{
    "clinical_study": {
        "@rank": "48738", 
        "arm_group": {
            "arm_group_label": "POL7080,  Anti-pseudomonal antibiotics", 
            "arm_group_type": "Experimental", 
            "description": "POL7080 administered daily"
        }, 
        "brief_summary": {
            "textblock": "To study the blood concentrations of POL7080 in patients who developed pneumonia due to\n      Pseudomonas aeruginosa following mechanical ventilation."
        }, 
        "brief_title": "Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ventilator Associated Pneumonia", 
            "Lower Respiratory Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pseudomonas Infections", 
                "Respiratory Tract Infections", 
                "Pneumonia, Ventilator-Associated"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Patients will be recruited after a written informed consent from the legal\n           representative or relative.\n\n        -  Adverse events will be coded using Medical dictionary for Regulatory Activities\n           (MedDRA).\n\n        -  Descriptive statistics will be used for the safety and efficacy variables."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female patients \u226518 years of age diagnosed with VAP , i.e., pneumonia that\n             arises more than 96 hours after endotracheal intubation documented or suspected to be\n             due to Pseudomonas aeruginosa\n\n          2. Respiratory specimen suitable for culture and Gram stain collected before starting\n             the treatment\n\n          3. Written Informed consent from the patient's legally acceptable representative or a\n             relative\n\n        Exclusion Criteria:\n\n          1. Patients with known hypersensitivity to fluoroquinolones, carbapenems, cephalosporin,\n             penicillin (beta-lactam antibiotics) or aminoglycoside antibiotics (i.e. all\n             available SoC antibiotics); patients with a clinically significant history of drug\n             allergies and history of anaphylactic reaction and patients with active allergic\n             conditions at the time of screening\n\n          2. Known or suspected pulmonary conditions which are likely to interfere with the\n             therapeutic response or might have additional impact on pharmacokinetics\n\n          3. Patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) score >25\n\n          4. Presence of septic shock at the time of evaluation for study entry\n\n          5. History of lung transplant\n\n          6. Patients with known HIV infection with CD4+ (cluster of differentiation 4) cell count\n             < 200/mm3\n\n          7. Concomitant morbidity of such severity that the patient is likely to die or present\n             with serious medical conditions within 7 days of study entry\n\n          8. Patients who are currently enrolled in, or have not yet completed at least 30 days\n             since ending another investigational device or drug trial or are receiving other\n             investigational agent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096328", 
            "org_study_id": "POL7080-003"
        }, 
        "intervention": {
            "arm_group_label": "POL7080,  Anti-pseudomonal antibiotics", 
            "description": "Intravenous infusion", 
            "intervention_name": "POL7080", 
            "intervention_type": "Drug", 
            "other_name": "POL7080"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ventilator Associated Pneumonia (VAP)", 
            "Lower respiratory infection", 
            "POL7080", 
            "Pseudomonas aeruginosa", 
            "Nosocomial pneumonia"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "ATTIKON University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "SOTIRA Pulmonary Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Hospital EVANGELISMOS"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Hospital KORGIALENIO-BENAKIO E.E.S"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Del Mar"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Bellvitge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Clinic San Carlos"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Joan XXIII"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital La Fe"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection.", 
        "other_outcome": [
            {
                "description": "Clinical cure will be measured based on clinical signs and symptoms and radiological findings.", 
                "measure": "Clinical cure", 
                "safety_issue": "No", 
                "time_frame": "Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34"
            }, 
            {
                "description": "Reduction in CFU/mL (colony forming unit /mL) of Pseudomonas aeruginosa in the daily quantitative cultures.", 
                "measure": "Reduction in bacterial count", 
                "safety_issue": "No", 
                "time_frame": "Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34"
            }
        ], 
        "overall_contact": {
            "email": "Klaus.Dembowsky@polyphor.com", 
            "last_name": "Klaus Dembowsky, MD", 
            "phone": "+41 61 567 16 00"
        }, 
        "overall_contact_backup": {
            "email": "Manickam.Rangaraju@polyphor.com", 
            "last_name": "Manickam Rangaraju, MD", 
            "phone": "+41 61 567 16 00"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Clinic, Barcelona, SPAIN", 
                "last_name": "Antoni Torres, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ATTIKON University Hospital, Athens, GREECE", 
                "last_name": "Evangelos Giamarellos-Bourboulis, MD PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Greece: Ministry of Health and Welfare"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PK profile of POL7080 will be determined on Day 3 and Day 6.", 
            "measure": "To measure the plasma concentrations of POL7080", 
            "safety_issue": "No", 
            "time_frame": "Day 3 and Day 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of adverse events reported by the patients or observed by the investigator will be recorded. Onset, end date, severity, causal relationship, outcome and measures taken will be summarized. Death, discontinuations and serious adverse events will be listed and narrative summaries will be provided.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Daily assessment up to 34 days from informed consent."
            }, 
            {
                "description": "The number and severity of blood chemistry and hematology abonrmal findings will be summarized descriptively and compared to baseline. Clinically significant values/outliers will be listed and commented.", 
                "measure": "Laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Day 4, Day 6, Day 10, Day 15, Day 24 and Day 34"
            }
        ], 
        "source": "Polyphor Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polyphor Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}